News – BioTuesdays

Developments

BlueRock co-founder, Gordon Keller, receives 2020 Bloom Burton award

Gordon Keller, Ph.D., co-founder of BlueRock Therapeutics, received the 2020 Bloom Burton award, which honors an individual who has made the most significant contribution to Canada’s innovative healthcare industry. In...

November 26, 2020

Developments

Urovant Sciences vibegron fails Phase 2a IBS trial

Urovant Sciences (NASDAQ:UROV) reported disappointing topline results from its Phase 2b trial of vibegron for the treatment of abdominal pain due to irritable bowel syndrome (IBS) in women. The study failed to meet its...

November 25, 2020

Developments

FDA clears Neuronetics TouchStar protocol for major depressive disorder

The FDA cleared Neuronetics’ (NASDQ:STIM) TouchStar protocol for the treatment of major depressive disorder. TouchStar is a three-minute intermittent theta burst protocol administered using the company’s NeuroStar...

November 24, 2020

Developments

Capricor initiates dosing in Phase 2 COVID-19 trial

Capricor Therapeutics (NASDAQ:CAPR) dosed the first two patients in its Phase 2 trial evaluating CAP-1002 for the treatment of severe COVID-19. CAP-1002 is an intravenously delivered allogeneic cardiac cell therapy...

November 24, 2020

Developments

Oramed initiates Phase 3 oral insulin trials

Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) began screening patients for its two Phase 3 trials evaluating ORMD-0801 for the treatment of Type 2 diabetes. The trials will enroll a total of 1,125 Type 2 diabetes patients...

November 24, 2020

Developments

PolyPid D-PLEX100 gets FDA breakthrough therapy designation

The FDA granted PolyPid’s (NASDAQ:PYPD) D-PLEX100 breakthrough therapy designation for the prevention of surgical site infections in patients undergoing colorectal surgery. D-PLEX100 is designed to provide prolonged...

November 24, 2020

Markets

Analysts start SQZ Biotechnologies at buy

Analysts with Stifel and BTIG launched coverage of SQZ Biotechnologies (NYSE:SQZ) with “buy” ratings and price targets of $38 and $40, respectively. The stock closed at $27.62 on Nov. 23. “We believe SQZ’s Cell Squeeze...

November 24, 2020

Markets

HCW starts Curis at buy; PT $5

H.C. Wainwright initiated coverage of Curis (NASDAQ:CRIS) with a “buy” rating and price target of $5. The stock closed at $1.35 on Nov. 23. Curis is developing two novel therapeutics for three potential indications that...

November 24, 2020

Developments

iBio receives U.S. patent for endostatin peptides for the treatment of fibrosis

iBio (NYSE AMERICAN:IBIO) received a patent from the U.S. Patent and Trademark Office, covering a novel expression cassette that enhances the yield of endostatin fragments and variants using iBio’s FastPharming System...

November 24, 2020

Developments

FDA clears Orchard Therapeutics IND for OTL-200

The FDA cleared Orchard Therapeutics’ (NASDAQ:ORTX) IND for OTL-200, a stem cell-based gene therapy for the treatment of metachromatic leukodystrophy (MLD). MLD is caused by a mutation in the arylsulfatase-A gene, which...

November 23, 2020

Developments

FDA approves Eiger’s Zokinvy for progeria

The FDA approved Eiger BioPharmaceuticals’ (NASDAQ:EIGR) Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare and fatal disease caused by a...

November 23, 2020

Markets

Analysts start Biodesix at buy and OP

200 Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Biodesix (NASDAQ:BDSX) with “buy” and “outperform” ratings. Shares of Biodesix closed at $17.09 on Nov. 20. Canaccord analyst Max Masucci...

November 23, 2020

BlueRock co-founder, Gordon Keller, receives 2020 Bloom Burton award

Urovant Sciences vibegron fails Phase 2a IBS trial

FDA clears Neuronetics TouchStar protocol for major depressive disorder

Capricor initiates dosing in Phase 2 COVID-19 trial

Oramed initiates Phase 3 oral insulin trials

PolyPid D-PLEX100 gets FDA breakthrough therapy designation

Analysts start SQZ Biotechnologies at buy

HCW starts Curis at buy; PT $5

iBio receives U.S. patent for endostatin peptides for the treatment of fibrosis

FDA clears Orchard Therapeutics IND for OTL-200

FDA approves Eiger’s Zokinvy for progeria

Analysts start Biodesix at buy and OP

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter